DelRicht Research is proud to highlight the outstanding performance of Dr. Patrick Dennis and the New Orleans site team at Touro Medical Center in a recent Phase 2 clinical trial evaluating an investigational therapy for adults with uncontrolled hypertension. The study, designed to assess safety and efficacy across 40 U.S. sites, sought to enroll 180 participants between April and July 2025. DelRicht’s enrollment target was five participants, yet our team exceeded expectations more than eightfold.

Surpassing Expectations Through Expertise and Engagement

Within weeks of activation, Dr. Dennis’s site screened its first participant, just 24 hours after activation, and went on to enroll 44 participants, representing 24.4% of total study enrollment. This achievement not only made DelRicht the top-performing site network in the study but also earned Dr. Dennis formal recognition as the #1 Enroller studywide.

The site’s rapid activation timeline, only 71 days from award to activation, reflects the efficiency of DelRicht’s centralized start-up model. By coordinating contracts, regulatory submissions, and site readiness through one streamlined process, our teams empower investigators to focus on what matters most: patient engagement, data integrity, and clinical excellence.

Overcoming Operational Challenges with Precision

The study presented challenges related to daily remote monitoring and device integration, which introduced some data-capture inconsistencies despite strong participant engagement. In addition, delays in confirming full enrollment status for one participant created temporary uncertainty around continuation status.

Rather than allowing these challenges to slow progress, DelRicht’s site team acted quickly, collaborating directly with the technology provider to troubleshoot issues and implementing an on-site quality check process to verify all readings. These proactive adjustments ensured data accuracy and maintained participant confidence throughout the study.

Equally important was the team’s clear and transparent communication. Study staff provided participants with timely updates on enrollment procedures, device use, and visit schedules, which minimized confusion and reinforced the trust essential to successful hypertension research.

Why Hypertension Research Matters

Hypertension remains one of the most prevalent and preventable contributors to cardiovascular disease worldwide, yet millions of adults continue to struggle with uncontrolled blood pressure despite available therapies. Research efforts like this Phase 2 study are critical to developing new treatment options and advancing understanding of long-term management strategies.

By embedding research directly within trusted community practices like Dr. Dennis’s, DelRicht helps ensure these innovations reach the diverse patient populations most affected by hypertension.

Proven Partnership and Performance

The success of this study underscores the strength of DelRicht’s model, combining experienced investigators, efficient operations, and patient-centered communication to deliver results that exceed expectations.

Highlights Include: 

– 44 participants enrolled (24.4% of total study enrollment)

– First patient screened within 24 hours of activation

– Site activated in just 71 days post-award

– Dr. Patrick Dennis recognized as Top Enroller studywide

DelRicht Research continues to advance clinical excellence through partnerships that accelerate discovery and deliver real-world impact for patients living with chronic conditions like hypertension.To learn more about partnering with DelRicht for your next cardiovascular or internal medicine program, visit www.DelRichtResearch.com or contact us to explore collaboration opportunities.